China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.
China Resources Pharmaceutical Group Ltd. has announced a major acquisition, with its subsidiary CR Boya Bio-pharmaceutical conditionally agreeing to purchase 100% of Green Cross HK for about RMB 1.82 billion, turning it into a non-wholly-owned subsidiary. Alongside the acquisition, a Strategic Cooperation Framework Agreement was signed to promote future business integration and pharmaceutical collaborations, although specific future projects remain subject to further agreements and market conditions.
For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.
